Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery

A Pilot Evaluation of the Efficacy of HistoScanning™ in Predicting the Presence and Location of Prostate Cancer in Men Undergoing Radical Prostatectomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02024178

Enrollment

Registered

2013-12-31

Start date

2011-06-30

Completion date

2012-05-31

Last updated

2016-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Prostate Cancer, Radical Prostatectomy, Ultrasound Imaging

Brief summary

This pilot clinical trial studies ultrasound imaging in finding prostate cancer in patients undergoing surgery. Diagnostic procedures, such as ultrasound imaging, may help find and diagnose prostate cancer. This study will serve as an analysis of the Histo-Scanning technology for the purpose of determining its ability to identify sites of prostate cancer at the time of prostate ultrasound.

Interventions

PROCEDUREUltrasound Imaging

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who have completed a staging multiparametric MRI at New York University (NYU) * Patients who plan to undergo radical prostatectomy by open or robotic approach

Exclusion criteria

* Previous History of Prostate Cancer Radiation Treatment * Focal Ablation of the prostate for cancer treatment * Men receiving hormonal ablation within 6 months prior to undergoing radical prostatectomy

Design outcomes

Primary

Measure	Time frame	Description
Correlation of Histoscan findings with Radical Prostatectomy Pathology	up to 3 years	Compare location and concordance of findings on pre-op MRI & Histoscan with radical prostatectomy specimen

Secondary

Measure	Time frame	Description
Extent of tumor and grade in treatment planning	Up to 3 years	Describe correlation between tumor grade on final pathology and histoscan findings

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026